Ganeden Biotech and Schiff Nutrition International, Inc. (NYSE: WNI), a leading nutritional supplement company, announced they will partner to fund a study led by the University of Reading, London, England. The study will determine the effects of GanedenBC30 on mature healthy adults with changing immunity and gastro intestinal needs.
GanedenBC30 (Bacillus coagulans GBI-30 6086) is a patented natural probiotic manufactured by Ganeden Biotech that has been shown to support the immune and digestive systems. In June 2011, Schiff purchased the rights to Ganeden’s probiotic GanedenBC30 for the supplement business and developed the Schiff Sustenex and Digestive Advantage lines of probiotic products.
Glenn Gibson, professor of Food Microbial Sciences at the University of Reading and president and founding member of the International Scientific Association for Probiotics and Prebiotics is senior author of the study, titled, “A randomized, double-blind, placebo controlled cross over study to determine the effect of probiotic GanedenBC30 on the immune function and gut microbiota of elderly persons.”
Gibson stated: “When you are younger, you have a healthier balance of good and bad bacteria. As people age, this shifts and often the bad bacteria in the gut increases. In addition, people begin to experience more gastro-intestinal (GI) issues, along with changes in immune function as the majority of your immune cells are in the gut. The goal of the study is to determine if we give a probiotic to a healthy, aging population of 60 years or older, can the GI flora revert back to its original form?”
While most strains of good bacteria need to be delivered in capsule form, Ganeden’s probiotic delivery system is different—it can be consumed in a variety of foods and beverages such as muffins, yogurt, bars, and even tea, and is the probiotic included in Schiff Nutrition supplements, Sustenex and Digestive Advantage.
“This study is mutually beneficial for Ganeden and Schiff,” said David Keller, Vice President of Scientific Operations, Ganeden Biotech. “Our hope is to gain a better understanding of the gut with age and to further establish that GandenBC30 can help support GI and immune health.”
“This trial demonstrates Schiff’s commitment to building strong science and innovation capabilities that benefit our product development initiatives,” stated Shane E. Durkee, Senior Vice President Research and Development, Schiff Nutrition. “We look forward to continuing our strategic relationship with Ganeden as we collaborate on this study to determine the effects of GanedenBC30 on important areas of human health, such as immunity.”
As the study title suggests, it will be a prospective, double-blind, placebo controlled, randomised, single centred cross-over study in 40 healthy elderly (65-80 years old) individuals. The study will consist of a four month randomised, double blind, cross-over treatment period with GanedenBC30 and Placebo.
Study enrollment will begin in June in London with anticipation of results in late 2012.